Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 27 04:00PM ET
23.07
Dollar change
0.00
Percentage change
0.00
%
IndexRUT P/E- EPS (ttm)-2.96 Insider Own5.11% Shs Outstand84.83M Perf Week0.17%
Market Cap1.96B Forward P/E- EPS next Y-2.86 Insider Trans0.00% Shs Float80.62M Perf Month-5.49%
Income-209.36M PEG- EPS next Q-0.95 Inst Own100.40% Short Float10.33% Perf Quarter8.16%
Sales0.00M P/S- EPS this Y-25.99% Inst Trans7.03% Short Ratio6.89 Perf Half Y46.38%
Book/sh6.53 P/B3.53 EPS next Y23.95% ROA-37.72% Short Interest8.33M Perf Year5.15%
Cash/sh6.72 P/C3.43 EPS next 5Y- ROE-40.98% 52W Range11.22 - 25.34 Perf YTD6.76%
Dividend Est.- P/FCF- EPS past 5Y-0.41% ROI-37.74% 52W High-8.96% Beta1.03
Dividend TTM- Quick Ratio10.00 Sales past 5Y1801.91% Gross Margin- 52W Low105.71% ATR (14)1.14
Dividend Ex-Date- Current Ratio10.00 EPS Y/Y TTM-20.58% Oper. Margin0.00% RSI (14)51.78 Volatility4.37% 5.22%
Employees184 Debt/Eq0.00 Sales Y/Y TTM-100.00% Profit Margin- Recom1.25 Target Price35.18
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q-61.13% Payout- Rel Volume0.00 Prev Close23.07
Sales Surprise- EPS Surprise-3.26% Sales Q/Q- EarningsFeb 27 AMC Avg Volume1.21M Price23.07
SMA20-0.16% SMA503.33% SMA20021.62% Trades Volume0 Change0.00%
Date Action Analyst Rating Change Price Target Change
Jan-31-24Downgrade Scotiabank Sector Outperform → Sector Perform $36 → $23
Dec-22-23Initiated Mizuho Buy $45
Oct-25-23Initiated BofA Securities Buy $29
Oct-11-23Initiated Goldman Buy $30
Jul-27-23Initiated Scotiabank Sector Outperform
Jul-11-23Initiated Guggenheim Buy $40
Apr-17-23Resumed BTIG Research Buy $34
Jan-31-23Initiated Stifel Buy $37
Jan-03-23Initiated JP Morgan Overweight $41
Jul-28-22Resumed B. Riley Securities Buy $31
Today 07:00AM
06:00AM
Mar-26-24 04:05PM
Mar-18-24 07:00AM
Mar-03-24 08:29AM
04:05PM Loading…
Mar-01-24 04:05PM
Feb-28-24 01:10PM
Feb-27-24 04:47PM
04:05PM
Feb-26-24 08:50AM
07:00AM
Feb-20-24 04:05PM
Feb-02-24 04:05PM
Feb-01-24 04:10PM
Jan-09-24 01:51PM
04:05PM Loading…
Jan-05-24 04:05PM
Jan-02-24 04:05PM
07:00AM
Dec-19-23 04:16PM
Dec-18-23 02:58PM
Dec-14-23 11:07PM
04:00PM
Dec-12-23 12:00PM
Dec-11-23 07:30AM
Dec-10-23 05:00PM
Dec-05-23 01:34PM
Dec-04-23 07:00AM
Dec-01-23 04:05PM
Nov-21-23 09:00AM
Nov-07-23 07:00AM
12:16PM Loading…
Nov-04-23 12:16PM
Nov-03-23 04:05PM
09:56AM
Nov-02-23 07:29PM
04:52PM
04:05PM
09:00AM
09:00AM
Oct-27-23 11:51AM
Oct-26-23 07:00AM
Oct-24-23 07:00AM
Oct-06-23 04:05PM
Oct-02-23 07:00AM
Sep-29-23 04:05PM
Sep-01-23 04:05PM
Aug-31-23 04:05PM
Aug-04-23 04:05PM
Aug-03-23 05:10PM
04:05PM
Jul-25-23 07:00AM
Jul-24-23 07:00AM
Jul-07-23 04:05PM
Jun-02-23 04:05PM
May-24-23 07:00AM
May-09-23 09:51AM
May-08-23 04:55PM
04:05PM
May-01-23 07:00AM
Apr-13-23 04:05PM
Apr-07-23 04:05PM
Apr-05-23 06:00PM
Apr-03-23 06:15PM
Mar-30-23 07:00AM
Mar-27-23 06:15PM
Mar-21-23 06:00PM
Mar-15-23 06:00PM
04:05PM
Mar-14-23 06:15PM
Mar-06-23 04:05PM
01:06AM
Feb-28-23 04:03PM
Feb-24-23 09:00AM
Feb-21-23 06:00PM
07:00AM
Feb-14-23 10:37AM
07:00AM
Feb-13-23 06:00PM
Feb-09-23 01:35PM
Feb-08-23 09:00AM
Feb-07-23 06:00PM
Feb-06-23 08:50AM
Feb-01-23 06:00PM
Jan-23-23 06:00PM
07:40AM
Jan-20-23 08:50AM
07:34AM
Jan-19-23 10:26AM
Jan-18-23 12:00PM
Jan-17-23 06:15PM
09:36AM
Jan-16-23 09:40AM
Jan-11-23 06:15PM
09:38AM
Jan-10-23 01:16PM
Jan-06-23 01:50PM
07:58AM
Jan-04-23 12:20PM
12:16PM
09:55AM
08:50AM
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development of cancer therapies. Its product candidates include SNDX-5613 and SNDX-6352. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Morrison BriggsDirectorAug 09 '23Option Exercise8.7752,855463,53870,691Aug 10 06:50 AM
Morrison BriggsDirectorAug 09 '23Sale18.2752,855965,40217,836Aug 10 06:50 AM
Meury WilliamDirectorAug 02 '23Option Exercise8.0283,000665,25083,000Aug 03 09:12 AM
Meury WilliamDirectorAug 02 '23Sale20.4683,0001,697,81048,000Aug 03 09:12 AM
Morrison BriggsDirectorJul 10 '23Option Exercise8.7752,855463,53870,691Jul 11 09:23 AM
Morrison BriggsDirectorJul 10 '23Sale20.4052,8551,078,06817,836Jul 11 09:23 AM
Goldan Keith A.Chief Financial OfficerJun 13 '23Sale22.3157712,8732,628Jun 14 04:20 PM
Morrison BriggsDirectorJun 09 '23Option Exercise7.6652,855404,78770,691Jun 09 05:32 PM
Morrison BriggsDirectorJun 09 '23Sale21.1852,8551,119,42117,836Jun 09 05:32 PM
Morrison BriggsDirectorMay 09 '23Option Exercise6.3852,855337,21570,691May 10 04:11 PM
Morrison BriggsDirectorMay 09 '23Sale21.4152,8551,131,47817,836May 10 04:11 PM
Morrison BriggsDirectorApr 10 '23Option Exercise6.3852,855337,21570,691Apr 12 04:03 PM
Morrison BriggsDirectorApr 10 '23Sale19.5352,8551,032,23717,836Apr 12 04:03 PM